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Abstract  
Background: The lack of progress in developing and delivering new therapies for 
hepatocellular carcinoma (HCC) is in part attributed to the risk related avoidance of tumour 
biopsy at diagnosis. Circulating tumour cells (CTCs) are a potential source of tumour tissue 
that could aid biological or biomarker research, treatment stratification and monitoring. 
 
Methods: An imaging flow cytometry method, using immunofluorescence of cytokeratin, 
EpCAM, AFP, glypican-3 and DNA-PK together with analysis of size, morphology and DNA 
content, for detection of HCC CTCs was developed and applied to 69 patient and 31 control 
samples. The presence of CTCs as a prognostic indicator was assessed in multivariate 
analyses encompassing recognised prognostic parameters. 
 
Results: Between 1 and 1642 CTCs were detected in blood samples from 45/69 HCC patients 
compared to 0/31 controls.  CTCs positive for the epithelial markers cytokeratin and EpCAM 
were detected in 29% and 18% of patients respectively, while an additional 28% of patients 
had CTCs negative for all markers other than size and evidence of hyperploidy. CTC number 
correlated significantly with tumour size and portal vein thrombosis (PVT).  The median 
survival of patients with >1 CTC was 7.5 months versus >34 months for patients with <1 CTC 
(p <0.001, Log rank), with significance retained in a multivariate analysis (HR 2.34, 95% CI 
1.005-5.425, p=0.049) including tumour size and PVT. 
 
Conclusions: The use of multiple parameters enhanced HCC CTC detection sensitivity, 
revealing biological associations and predictive biomarker potential that may be able to guide 
stratified medicine decisions and future research. (Word count, 247)  
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Lay summary 
Characteristics of tumour tissues can be used to predict outcomes for individual patients with 
cancer, as well as help to choose their best treatment. Biopsy of liver cancers carries risks, 
however, and is usually avoided.  Some cancer cells enter the blood, and although they are 
very rare, we have developed a method of finding and characterising them in patients with 
liver cancer, which we hope will provide a low risk means of guiding treatment.  
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Introduction  
Hepatocellular Carcinoma (HCC) complicates chronic liver diseases (CLD) and, owing to a 
combination of incidence, late stage presentation and lack of therapeutic options, is the 
second commonest cause of cancer related death globally [1]. The predominant causes of 
CLD include hepatitis B and hepatitis C, although the prevalence of obesity and alcohol excess 
are having a major impact, with mortality continuing to rise despite advances in antiviral 
therapy [2].  The presence of associated CLD severely limits the role of traditional anti-cancer 
cytotoxic agents in patients with HCC. While ‘targeted’ medical therapies have emerged for 
other cancer types in recent years, advances for patients with HCC have been hampered by 
both a failure to identify or successfully ‘drug’ the key drivers of hepatocarcinogenesis, as well 
as an inherent lack of biological markers to support stratification of both traditional and 
emerging therapies.  This handicap is attributed to the lack of tissue biopsy as standard 
diagnostic practice for patients with HCC. In the majority the diagnosis can be confidently 
made using imaging criteria, avoiding biopsy and the associated risks of haemorrhage and 
tumour seeding [3].  There is a need, therefore, for HCC biomarkers other than those acquired 
by standard staging or tissue biopsy, that can be used to assist treatment stratification and to 
determine prognosis. The development of a ‘liquid biopsy’ enabling evaluation at multiple time 
points would be a major advance.  
 
First described by Thomas Ashworth in 1869, circulating tumour cells (CTCs) are those cells 
that have detached from a primary or secondary tumour and can be detected in the peripheral 
circulation [4].  Although the potential significance of these cells has long been realised, clinical 
implementation has been slow owing to a lack of cancer-specific biomarkers and difficulties 
detecting these rare cells (estimated frequency ≤1 CTC/ml of blood) against a high 
background of haematopoietic cells and blood components.  Recent technological advances 
have started to have an impact in metastatic breast, prostate and colorectal cancers, where 
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CTCs positive for epithelial biomarkers such as cytokeratin (CK) and epithelial cell adhesion 
molecule (EpCAM) have been detected using immunogenic capture with the CellSearch® 
system (Janssen Diagnostics) and enumeration of CTCs shown to be a useful predictor of 
prognosis in terms of median overall survival and time to progression [5-7].   
 
Currently, there are limited studies detecting and characterising CTCs in HCC, with no 
standardisation of methods and techniques.  CTC detection of ≥1 or 2 CTC using the 
CellSearch system is reportedly in the region of 30-35%, although positive cells have 
occasionally been detected in controls [8-10].  An alternative size based filtration technique 
(Isolation by Size of Tumour cells or ISET®) identified cells presumed to be CTCs during 
tumour resection in a study published in 2000, but with a sensitivity that could only detect 
these cells as ‘microemboli’ prior to surgery (3 of 7 patients), rather than as single cells [11].  
More recently, Morris and colleagues evaluated the ISET and CellSearch methods in patients 
with HCC, confirming a CellSearch sensitivity similar to that previously reported (15/50; 28%) 
compared to 100% (19 of 19 patients) for ISET [9].  While ISET sensitivity was promising, 
specificity was dependent on size only, with no associations in the small number of cases 
studied with tumour stage or outcome [9].  Other researchers have explored the use of positive 
immunomagnetic selection with mesenchymal markers in combination with alternative liver 
specific markers such as asiaglycoprotein receptors (ASPGR), or in-situ hybridisation to detect 
molecular aberrations (TP53 deletion, HER-2 amplification) [12, 13].  As with the other 
methods, the clinical relevance of detection of these populations of cells in patients with HCC 
remains to be determined. 
 
We have previously outlined a method for the detection and characterisation of CTCs using 
the Imagestream (Amnis®, EMD Millipore) imaging flow cytometer [14].  Here we report our 
subsequent study in patients with HCC, using a combination of image, size and fluorescently 
detected biomarkers.  These included the epithelial biomarkers EpCAM and cytokeratin, HCC 
specific biomarkers AFP and glypican-3 (GPC3), as well as DNA-PK – a candidate biomarker 
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for treatment stratification in HCC [15]. We have detected at least 1 CTC in 65% (45/69) of 
patients, showing significant correlations between CTC number and adverse tumour 
characteristics.  Furthermore, the presence of CTCs was an independent predictor of poorer 
survival.  
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Patients and Methods 
Cell culture 
A panel of 6 authenticated HCC cell lines (LGC standards) were assessed for cell area.  
HepG2, Hep3B, Huh-7 and PLC/PRF/5 were cultured in Dulbecco’s modified eagle’s medium 
(DMEM) with 15mM HEPEs, pyridoxine and NaHCO3 (Sigma-Alrich, UK) supplemented with 
10% foetal bovine serum (FBS), (Gibco, UK) and 2.5% 200mM L-Glutamine solution (Sigma-
Alrich, UK).  SNU182 and SNU475 cells were maintained in RPMI 1640 medium (Sigma-
Aldrich, UK) supplemented with 10% FBS.  Cells were maintained in the growth phase and 
passaged when ~70% confluent.  Regular mycoplasma testing was performed using the 
MycoAlert mycoplasma testing kit, Lonza, USA.   
 
Assessment of biomarker expression in HCC cell lines  
HCC cell lines were assessed for the expression of biomarkers using the Imagestream.  The 
SJSA1 human osteosarcoma bone fibroblast cell line was used as a negative control when 
assessing the expression of epithelial biomarkers.  A population of round single cells was 
gated by using a scatterplot of brightfield aspect ratio against area.  From this population in 
focus cells were selected by creating a histogram of the root mean square feature which 
detects differences in intensity between adjacent pixels.  A gate of in focus cells was created 
and assessed for the mean pixel intensity of biomarkers of interest.  Numerical data on 
different cell populations was exported to GraphPad Prism Software, version 6 (GraphPad 
Prism Software Inc, California, USA). 
Patient blood samples 
As part of a pilot project exploring the utility of the Imagestream in patients with HCC, blood 
samples were collected from patients attending the Newcastle upon Tyne Hospitals NHS 
Foundation Trust between November 2012 and January 2015.  With the initial aims of 
optimising enrichment and analysis methodologies, as well as assessing a panel of CTC 
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biomarkers, there was no patient selection criteria other than an established diagnosis of HCC, 
based on EASL-EORTC guidelines [3], and patient consent, aiming to collect 1 sample per 
week. Patients with an active malignancy at another site were excluded. Control samples were 
from 15 healthy volunteers and 16 patients with cirrhosis without cancer. Ethical approval was 
obtained through the Newcastle Hepatopancreatobiliary and Gastroenterology Research 
Tissue Biobank. The patient dataset included age, sex, body mass index (BMI),blood count 
and biochemistry, as well as tumour staging on cross-sectional imaging - tumour size, portal 
vein thrombosis (PVT), presence or absence of extra-hepatic disease (EHD). ECOG 
Performance Status score, Child-Pugh score and Barcelona Clinic for Liver Cancer (BCLC) 
stages were recorded, as were treatment regimens. Follow-up was until 15th September 2015, 
recording whenever possible the time to clinical progression and radiological progression 
using mRECIST (modified Response Evaluation Criteria in Solid Tumors) criteria [3], as well 
as date of death, from the date the blood sample for CTC analysis was taken.  
 
Patient sample processing 
Patient blood samples were collected in either EDTA (BD Vacutainer) or CellSave preservative 
tubes (Janssen Diagnostics).  EDTA tubes were transported on ice to the laboratory where 
they were processed immediately.  CellSave tubes were transported at ambient temperature 
and cells were left to fix for at least 1 hour.  A total of 4 ml blood was processed from EDTA 
samples and 8 ml from CellSave tubes and cell number for each sample expressed as number 
of cells per 4 ml whole blood. Patient samples were processed according to a previously 
developed method which reported recovery of 57.3, 49.2 and 59.0 % of cells spiked into whole 
blood at densities of 500, 50 and 5 per ml respectively [14]. Unfortunately it was not possible 
to assess in-study sample reproducibility. Briefly, samples were blocked using BSA solution 
and FcR block (MACS®, Miltenyi) to prevent unspecific antigen reactions.  The samples were 
depleted of red blood cells (RBCs) by incubation with BD Phosflow™ lyse/fix red cell lysis 
buffer (BD Biosciences).  The sample was then immunomagnetically depleted of white blood 
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cells (WBCs) using a CD45 depletion kit and BigEasy magnet (StemCell Technologies).  The 
remaining cell suspension was then stained with a series of immunofluorescent antibodies 
including: pan-CK (CK -4, -5, -6, -8, -10, -13 and -18), EpCAM, AFP, GPC3, DNA-PK and 
CD45 (Supplementary Table S1).  Nuclei were stained with either DRAQ5 or DAPI.  
Following staining, cells were washed and re-suspended in PBS prior to processing through 
the Imagestream.  Analysis was performed using the IDEAS software (Amnis, Seattle) and 
CTCs were identified on the basis of brightfield morphology, size, antigen expression, nuclear 
signal and the absence of CD45 expression.  Objects that did not meet these criteria but had 
a consistent cell morphology and lack of CD45 expression were also identified.  Cell area was 
calculated by creating a custom brightfield mask based on the standard brightfield mask 
eroded by 3 pixels to allow closer fit to the brightfield image.  A new area feature of this mask 
was created and area values calculated in µm2. 
 
Statistical Methods 
 
Statistical analyses were carried out using SPSS, version 21 (SPSS Inc. Chicago, USA) 
licensed to Newcastle University and GraphPad Prism Software, version 6 (GraphPad Prism 
Software Inc, California, USA).  Bivariate associations were Pearson or Spearman’s Rho 
correlations for parametric or non-parametric data respectively. Differences between groups 
of continuous variables were assessed by t-test (parametric data) or Mann-Whitney (non-
parametric data) tests. Differences between categorical variables were assessed by Pearson 
Chi square, or Fisher’s exact tests approximated using a Monte Carlo approach where cells 
within a contingency table of greater than 2 x 2 contained low numbers (<5). A p value of <0.05 
was considered significant. Survival was recorded as months from blood sampling for CTC 
detection to 15/09/2015. Differences in cumulative survival were determined using the Kaplan-
Meier method and a Log-Rank test. The Cox proportional hazards-regression model was used 
to identify parameters associated with survival. Factors initially considered by univariate 
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analysis included age, body mass index (BMI), T2DM, number of tumours, size of largest 
tumour, presence of PVT or EHD, ascites or encephalopathy, serum alpha-fetoprotein (AFP), 
serum albumin, serum bilirubin, prothrombin time, performance status and treatment. A cutoff 
of p <0.05 was used to select variables entered into the multivariate model.  
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Results  
Biomarker heterogeneity between and within HCC cells 
 
We initially characterised biomarker staining profiles of HCC cells lines with antibodies to 
EpCAM, CK, AFP and GPC3. Suspended cells trypsinised, suspended and stained prior to 
analysis by the Imagestream. Round single cells were identified by creating a scatterplot of 
brightfield aspect ratio against area as described in the methods.  After additional gating to 
exclude double cells or debris, the in focus single cell population was assessed for the mean 
pixel intensity of the biomarker of interest, as an estimate of biomarker expression. 
Heterogeneity was observed between the HCC cell lines studied, as shown in Figure 1A-D.  
Hep3B cells for example had the highest expression of EpCAM, AFP and GPC3, but the 
lowest expression of cytokeratin. SNU182 cells had high levels of cytokeratin and EpCAM, 
with relatively low levels of GPC3.  PLC/PRF/5 and SNU475 had particularly low levels of 
GPC3.  More striking than the differences between the cell lines, was the differences within 
the HCC cell lines.  The range of pixel intensity included negative cells in all cases, including 
an EpCAM negative subpopulation in Hep3B cells.  While these data highlight the importance 
of using more than one epitope for CTC detection, they also highlight the variability of 
expression even within cultured cell populations arising from the same tumour.  Ideally, 
therefore, CTC detection should be based on additional characteristics less subject to change. 
 
Imagestream discrimination of CTC from white blood cells on the basis of size  
 
During analysis of both HCC cell lines and patient samples following depletion, data analysis 
files produced following compensation frequently contained biomarker negative objects >50 
µm in diameter.  Some of these were clusters of CD45 +ve WBCs escaping depletion.  Other 
larger nucleated cells were CD45 –ve and suspected to be biomarker negative CTCs. There 
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has been debate as to whether or not CTCs can be identified simply on the basis of size.  The 
ISET filtration enrichment method relies on CTC size, but potentially lacks specificity without 
additional characterisation of candidate cells. CTCs may also escape retention by this method 
consequent to their deformability [16]. The Imagestream enables objective characterisation of 
the size of the high-resolution brightfield images. Thus we assessed the surface area of the 
brightfield images of the circulating cells, as shown in Figure 2A.  The surface area of 
CD45+ve WBCs of our volunteers and patient cohort (mean 88.3 ± 0.20 µm2) was compared 
that to the surface area of HCC cell lines and CTCs (Figure 2B). The HCC cells were 
distinguishably larger than WBCs, ranging from HepG2 (219.5 ± 54.1 µm2) to SNU475 (402.7 
± 2.9 µm2).  The area of single cell images in distinct biomarker negative and positive 
populations of CTCs was analysed (n=11 and n=7 cases respectively). The average area of 
biomarker positive CTCs (mean area of 362.2 ± 55.5 µm2) was comparable to that of HCC cell 
line cells, with no overlap with the WBC population, and was similar to the area of biomarker 
negative CTCs (345.2  ± 38.4    µm2, Figure 2B). Interpatient heterogeneity in area of CTC 
images, between biomarker positive and negative cells, was also similar in the two patients 
with CTC counts greater than 100 (Figure S1). Therefore, after gating to exclude doublet cells 
and debris, CTCs could be detected by Imagestream on the basis of size, even in the absence 
of classical biomarker expression (Figure 2A and 2B).  The DNA assessment of biomarker 
negative cells confirmed that they were hyperploid, with more DNA than peripheral WBC, 
strengthening the case for these being tumour in origin.  
 
Imagestream detection of CTCs in 65% of patients with HCC.  
 
The HCC patient cohort described in Table 1 included 69 patients. Their median age was 73 
years, with 71% (49/69) having underlying cirrhosis.  Alcohol related and none alcohol related 
fatty liver diseases were the commonest etiologies, with 11.6% having no evidence of 
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underlying liver disease.  Although the majority (58/69) had preserved liver function classed 
as Childs Pugh stage of A, 72% (50/69) were classed as BCLC stage C, often on the basis 
either advanced tumour stage (PVT, EHD) or ECOG performance status of 1 or greater.  
Arterial intervention or supportive care were the commonest treatments, although 14 patients 
(20%) underwent potentially curative therapies (liver transplant, tumour resection or tumour 
ablation). Arterial treatment was typically with transarterial chemoembolization (TACE) with 
doxorubicin eluting beads, although one patient received selective internal radiotherapy 
treatment (SIRT) first line and four patients received second line SIRT, treating tumour 
progression post TACE.   In 40 of the 69 cases, the samples for analysis were taken before 
any therapeutic intervention, while in the remainder the samples were post treatment (median 
85 days).  CTCs were detected based on brightfield image characteristics and size in 45/69 
(65%) HCC patient blood samples compared to 0/31 control samples.  Control samples were 
from 15 healthy volunteers and 16 cirrhotic patients without cancer. The number of CTCs 
detected in patients was highly variable, with counts ranging between 1-1642 cells per 4 ml 
blood samples (Figure 2C).  Eleven patients had previously received curative therapy for other 
cancers (including lymphoma, breast, prostate, colorectal, oral, basal cell and superficial 
bladder cancers) without any sign of recurrence after a minimum of 3 years follow-up. 
 
Biomarker expression in HCC CTCs 
 
Inclusion of classical epithelial markers (EpCAM and CK) in the biomarker panel enabled 
comparisons with CellSearch data in the HCC literature. In addition, AFP was used as an HCC 
specific biomarker.  The expression of candidate biomarkers (GPC3 and DNA-PK) that could 
be useful in terms of diagnosis and treatment stratification were also explored.  As observed 
with HCC cell lines, expression of the classical epithelial and exploratory biomarkers was 
highly heterogeneous between patients and within the same patients, with examples of cases 
shown in Figure 3A-E.  CK was the most commonly detected biomarker (29%), followed by 
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DNA-PK (24%), AFP (20%), EpCAM (18%) and GPC3 (12.5%).  In total, 37% of cases had 
CTCs that had positive expression of one or more of the candidate biomarkers, while an 
additional 28% had CTCs that were negative for all included tumour biomarkers. 
 
Imagestream CTC number was associated with advanced tumour stage 
 
Samples were collected from HCC patients at various disease stages and undergoing different 
treatment regimens (Table 1).  In the whole cohort, weak correlations between CTC number 
and some adverse prognostic features were observed, including a weak correlation with the 
size of the largest tumour (0.291, p=0.015, Spearman’s Rho Figure 4). Consequently, the 
sensitivity of Imagestream CTC detection was explored in cases with tumours below or equal 
to 2 cm in widest diameter on imaging compared to those with one or more HCC greater than 
2 cm. At least 1 CTC per 4 ml blood sample was detected in 9/15 (60%) cases with an HCC 
<2 cm versus 36/54 (67%) cases with HCC >2 cm, which was not significantly different 
(p=0.632; Chi square test).  Limiting the comparison to cases where greater than 1 CTC per 
4 ml were detected, the comparative figures were 5/15 (33%) and 27/54 (50%) (p=0.252; Chi 
square test).  In the whole cohort, there was also a weak correlation between CTC number 
and the presence of encephalopathy (0.336, p=0.005; Spearman’s Rho test).  41/65 patients 
without encephalopathy had CTCs detected, with a median CTC number of 1, compared to 
CTCs detected in 4/4 patients who did have encephalopathy, with a median CTC number of 
10. 
 
Associations within and between the different biomarker categories of CTC were also 
explored.  The strongest association was between numbers of cytokeratin and AFP positive 
CTC (0.786, p<0.0001), with highly significant correlations also between numbers of EpCAM 
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and cytokeratin positive cells (0.497, p<0.0001) and AFP positive cells (0.463, p<0.0001). 
GPC3 expression correlated with EpCAM (0.405, p=0.024) and no other epithelial biomarker.  
Taken individually, the numbers of biomarker positive cases were relatively small, without 
significant correlations with stage of disease.  As a group, numbers of biomarker positive CTCs 
trended toward an association with tumour size (0.236, p=0.05), with a weak negative 
correlation with serum albumin (-0.354, p=0.003) and weak positive association with the 
presence of encephalopathy (0.331, p=0.005).  The numbers of biomarker negative cells 
correlated with none of the other biomarkers, but there were indications of an association with 
numbers of neutrophils (0.240, p=0.049) in the peripheral blood count taken on the same day.  
In addition, numbers of biomarker negative CTCs were weakly associated with the presence 
of PVT (0.348, p=0.004; Spearman’s Rho test). 12/14 patients with a PVT had CTC detected 
and in 10 of these cases, CTCs were epithelial biomarker negative.  
 
The presence CTCs was associated with poorer Survival 
 
Associations with overall survival were explored by univariate cox regression, as shown in 
Table 2A.  Significant associations included the number of CTCs per 4 ml blood sample 
(p=0.043), tumour size (p<0.0001) and the presence of either a PVT (p=0.002) or EHD 
(p<0.0001).  CTCs and presence of PVT or EHD were independent of each other in a 
multivariate analysis (Table 2A).  Notably, while the presence or absence of CTC was not 
significantly associated (p=0.127), survival comparing those individuals with 0 or 1 CTC per 4 
ml blood sample (n=37; 54%) to those with >1 CTC per 4 ml blood (n=32; 46%) was markedly 
different (threshold of >1 was determined by ROC analysis, optimal cut off >1.250, sensitivity 
68.75%, specificity 72.97, likelihood ratio 2.544). The median survival was in excess of 34 
months in the former group, compared to 7.5 months in the latter (p<0.0001, Kaplan Meier 
with Log Rank test, Figure 5A).  This ‘cut off’ remained significant in a multivariate analysis 
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(p=0.049, HR 2.34, 95% CI 1.005 – 5.425) (Table 2B).  Disease progression was not protocol 
driven in this case series and time to progression (TTP) was estimated based on imaging 
performed as part of standard care, or clinical deterioration changing the BCLC stage. Four 
patients died without documented progression and were excluded from TTP analyses.  Similar 
to the survival data, TTP between those with or without >1 CTC per 4 ml blood was significantly 
different (p=0.006 Kaplan Meier with Log Rank test, Figure 5B).  
 
Analyses pre and post treatment were limited in this small case series, as was the possibility 
to explore associations within specific biomarker or treatment groups.  Considering only the 
40 cases where samples were taken at diagnosis and staging, CTC >1 per 4 ml blood, tumour 
size, PVT and EHD were each associated with poorer survival, although only the presence of 
PVT was significant in a multivariate analysis (data not shown).  In the post treatment group 
(n=29), TTP and survival were significantly shorter in those with CTC >1 per 4 ml blood as 
shown in Figure 5C and D.  Both CTC number and tumour size remained independent 
predictors of poorer survival. Treated as a categorical variable, only CTC >1 per 4 ml blood 
was independently associated with poorer survival (HR 6.16, CI 1.71-22.33, p=0.006).  In the 
treated group, nineteen of the individuals received arterial therapy and similarly, CTC >1 per 
4 ml blood post treatment was the only factor significantly associated with a poorer survival 
(p=0.022, HR 5.02, 95% CI 1.26-19.93).   
Additional observations in blood samples from patients with HCC 
There were a range of other objects that were detected by the Imagestream that may have 
gone undetected using other methods.  In some patient samples, CTCs appeared to be 
travelling in aggregates (Figure 6A).  This has been previously described by researchers 
using the ISET method of CTC isolation. The survival outcome of patients with aggregates 
detected was comparable with that of patients with more than 1 CTC but no aggregates 
detected (Data not shown).  Occasionally, CTCs showed signs of cell division or bi-nucleation 
19 
 
(Figure 6B).  In some patients, CTCs appeared to have leucocytes attached to them (Figure 
6C).  This is suggestive of a tumour directed immune response and has not been previously 
described using other methods.  The clinical relevance of these observations are as yet 
unknown.  Cells significantly larger than CTC (895.9 ± 41.9 µm2 versus 255.3 ± 6.9; n=100 
paired t-test p<0.0001) and with a less circular morphology were detected (Figure 6D) in the 
majority of patients with HCC as well as controls.  These were classed as macrophages.
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Discussion  
 
Following initial method development, we have previously shown that the Imagestream can 
be used as a CTC detection platform for the enumeration of CTCs in different cancer types 
[14]. Here we have taken that work forward in patients with HCC, demonstrating that the 
Imagestream method detects epithelial biomarker positive CTCs in similar numbers of patients 
compared to other methods, but that it has several significant advantages. Increasing the 
number of biomarkers used to characterise cells identified additional CTCs - both in the same 
patients, but also in additional patients.  Furthermore, we have demonstrated that inclusion of 
a size criterion in combination with absence of CD45 positivity and brightfield image analysis 
captured all positive biomarker CTCs, but also identified biomarker negative candidate CTCs 
in an additional 28% of patients. In total, we have identified CTCs in 45/69 (65%) of our 
patients compared to none of 31 control subjects.  Notably, in contrast to other methodologies 
used to detect CTCs in patients with HCC, Imagestream enumeration demonstrated 
significant associations with advanced HCC stage as well as independent associations with 
patient survival.  
 
It has previously been suggested that reliance on epithelial markers for CTC detection may 
exclude the detection of a proportion of the CTC population that do not express these markers, 
or have lost expression consequent to the process of epithelial mesenchyme transition (EMT 
[17-19].  In this study, we have confirmed that not all HCC CTC detected do express the 
classical epithelial markers EpCAM and CK.  Some cells expressed one epithelial marker but 
not the other, while some expressed AFP and neither cytokeratin nor EpCAM.  This could 
partly explain the low detection rates in studies that have used CellSearch in HCC, as 
published CellSearch studies have relied on the expression of EpCAM for the 
immunomagnetic capture of CTCs and CK for their detection [9, 10, 13, 20].  In addition to the 
21 
 
detection of cells that did not express classical epithelial markers however, an additional 28% 
of patients had objects that were nucleated and cellular in morphology, negative for all 
biomarkers, but of a size typical of a CTC rather than any other blood cell. While it is difficult 
to ascertain with absolute certainty that these cells were CTCs, given the complex 
heterogeneity of HCC and the detection of many biomarker negative cells within HCC cell line 
populations, identifying additional cells negative for the biomarkers included was not 
surprising. The weak association of these cells with neutrophils raises the obvious question 
as to whether these might be white blood cells.  This is improbable, given the cells were CD45 
negative, dissimilar in both size and morphology from the white cells, with elevated DNA 
content.  Abnormal DNA content  has been reported in patients with cirrhotic dysplasia [21] – 
thus the elevated DNA content does not unequivocally identify cells as malignant. In our series 
thus far, however, these cells have not been detected in the circulation of any control subject, 
including 16 cirrhotic patients without cancer.  An interesting alternative hypothesis, 
particularly given the associations between biomarker negative cells, neutrophils and portal 
vein invasion, is that these biomarker negative objects are CTCs that have undergone EMT. 
EMT is associated with HCC progression with a suspected role for cancer associated 
neutrophils driving these processes [22, 23]. The inclusion of an additional biomarker, such 
as ASPGR - co-expressed in CTC with EMT markers vimentin and twist in association with 
portal vein invasion [24] - may allay any remaining doubts regarding the origin of these cells 
in future studies.   
 
In several HCC patients clusters of CTCs were identified as previously reported by 
researchers using the ISET method [11].  The significance is unknown, but others have 
suggested that CTCs travelling in clusters may be more likely to evade the immune system 
and promote metastatic spread by facilitating survival and growth of secondary lesions 
compared to single cells [25].  Immune interactions between single CTCs and WBCs were 
observed and these may be CTCs that are actively cleared/deactivated by immune cells and 
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therefore unable to establish metastases.  A counter argument, however, is that CTCs travel 
surrounded by leucocytes as a form of protection [17] and without larger studies – possibly 
including further characterisation of the CTC associated white cell population – the relevance 
of these interactions remains unknown.  Imagestream analyses are on fixed cells and future 
studies will likely benefit from complementary methods, to enable sorting and isolation of living 
cells, as well as their additional comprehensive characterisation or culture.  
In the present study, the principal aim was to develop relevant Imagestream methodologies 
and explore their utility.  We have shown how heterogenous biomarker expression in CTCs in 
the same patients can be, demonstrating the need for multiple biomarkers and additional 
criteria such as size and brightfield image to increase the sensitivity and specificity of CTC 
detection.  With this approach we have identified CTCs in 65% of our patients. While numbers 
of CTCs appeared to increase with tumour size, detection was not limited to large tumours.  In 
this small series we have observed weak associations with features alluding to tumour biology 
– including peripheral neutrophil count and portal vein invasion – and also shown independent 
CTC associations with patient survival.  Evidently these observations need confirmation in a 
prospective fashion in predefined patient groups. Furthermore, in larger series of surgically 
treated patients, it will be important to explore the relationship between CTC biomarker 
expression profiles with the immunohistochemistry profile of the tumour. However, this paper 
strongly supports CTC enumeration as a credible liquid biopsy tool.  In combination with the 
development of methods to detect and quantify potential stratification biomarkers, such as c-
MET, or pharmacodynamics markers for monitoring treatments, these tools are likely to have 
a major impact in the future management of our patients with HCC.  
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Figure Legends 
Figure 1. Heterogenous expression of biomarkers in HCC cell lines 
HCC cell lines included HepG2, Hep3B, Huh-7, PLC/PRF/5, SNU182 and SNU475), while 
SJSA1 osteosarcoma cells were used as a negative control for epithelial biomarkers.  Cells 
were stained with antibodies against A. EpCAM (conjugated to AF488); B. pan-CK (conjugated 
to PE); C. AFP (conjugated to AF594); D. GPC3 primary antibody and AF488 goat anti-mouse 
secondary antibody.  DAPI was used as a nuclear stain.  Cells were imaged using the 
ImageStream.  Single cells were gated based on brightfield area and aspect ratio.  In focus 
cells were selected using the root mean square feature and then assessed for the mean pixel 
intensity of the respective biomarkers using the IDEAS software.  Data analysis was after 
export to GraphPad Prism. Expression levels of each markers was different between the cell 
lines (Kruskal Wallis, p<0.001 in each case).    
 
Figure 2. CTCs can be distinguished by size and detected in 65% of patients with HCC 
Cell area was assessed after creating a brightfield mask, the histogram of brightfield area 
shown in (A).  The large peak of smaller area cells is that of single white blood cells.  Objects 
with an increased brigthfield area included doublets of white blood cells, three or more white 
blood cells and CTCs (A).  The brightfield area of single in-focus cells, including white  blood 
cells, HCC cell lines (HepG2, Hep3B, Huh-7, PLC/PRF/5, SNU182), biomarker positive CTCs 
and macropahges is shown in table form (B) with values displayed as mean ±SEM.  Panel (C) 
shows the number of CTCs per 4 ml of blood after CD45 immunomagnetic depletion in 69 
patients with HCC. *number of single cells from representative experiments, **number of 
patients in which the mean CTC area was assessed, ***number of cells pooled from patient 
samples. 
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Figure 3. Heterogenous expression of biomarkers in patients with HCC 
CTCs observed in HCC patient samples displayed heterogenous expression of biomarkers, 
as shown in individual patients. In case (A), distinct EpCAM-positive and cytokeratin (CK) -
positive CTCs were detected.  Cases B-C demonstrate CTCs that were positive for different 
combinations of EpCAM, CK, AFP and DNA-PK, including a CTC doublet positive for EpCAM 
and DNA-PK in (C). A GPC3-positive CTC is shown in (D).  (E) shows biomarker negative 
CTCs distinguished on cellular morphology, size and DNA content.  
 
Figure 4. CTC number correlates with tumour size  
Patients with larger tumours tended to have a greater number of CTC detected (0.291, 
p=0.015). Black dots represent patients samples taken before any treatment, while white dots 
are those from patients whose sample was taken post treatment.  
 
Figure 5. Greater than 1 CTC identifies patients with a poorer outcome 
In patients with HCC, those with >1 CTC per 4 ml blood had a poorer outcome, with a median 
survival of 7.5 months compared to >34 months (Kaplan Meier Log-Rank p<0.0001, 
multivariate analyses in Table 2) (A). Time to progression (TTP) first documented, either 
radiological or clinical, is shown Panel (B).  Similarly, in the subgroup of patients who had 
received treatment, the presence of >1 CTC per 4 ml blood was highly significantly associated 
with poorer survival (C) and shorter TTP (D). 
 
Figure 6. Additional CTC observations 
(A) Clusters of EpCAM-positive CTCs. (B) EpCAM-positive CTCs that appear to be mitotic. 
(C) CTCs with immune interaction - in this case an EpCAM-positive CTC is surrounded by 
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CD45-posiitve white blood cells that escaped depletion.  (D) Cells larger than CTCs, with less 
circularity, were presumed to be macrophages.   
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Table 1.  Patient cohort for CTC studies 
 
Table 1 
Cases  All  At 
presentation 
Post‐
treatment 
Number of cases  69  40  29 
Age (median)  73  74  69 
Liver disease 
None 
ALRD 
NAFLD 
PBC/AIH 
Haemochromatosis 
Cryptogenic 
8 
22 
24 
9 
4 
2 
6 
13 
12 
3 
4 
2 
2 
9 
12 
6 
0 
0 
Cirrhosis (present)  49  25  24 
Tumour number   1.9±0.2  1.9±0.2  1.8±03 
Tumour size (mm)   58±6  72±9  38±5 
PVT (present)  14  9  5 
EHD (present)  9  4  5 
Encephalopathy (present)  4  2  2 
Ascites (present)  6  5  1 
Childs Pugh A/B/C  58/8/3  31/6/3  27/2/0 
BCLC A/B/C/D  11/5/50/3  4/1/32/3  7/4/18/0 
PST 0/1/2/3  21/17/27/4  8/9/19/4  13/8/8/0 
AFP (median, kU/L) 
 
14 
(≤1‐≥50000) 
14 
(≤1‐≥50000) 
18.5 
(≤1‐≥50000) 
Albumin (g/l)  38.9±5.4  38.5±5.3  39.5±5.6 
Bilirubin (µmol/l)  18.2±15.4  19.0±15.3  17.2±15.8 
Prothrombin time (s)  12.6±2.5  12.9±2.7  12.3±2.3 
Primary Treatment 
Liver transplant 
Resection 
Ablation 
Arterial treatment 
Sorafenib 
Supportive care 
4 
3 
7 
27 
9 
19 
2 
2 
3 
7 
7 
19 
2 
1 
4 
20 
2 
0 
 
The cohort of 69 patients studied included 40 recruited during their diagnostic and staging 
work-up, and 29 patients attending outpatient follow-up post treatment. The majority had 
either alcohol related liver disease (ARLD) or non-alcoholic fatty liver disease (NAFLD). 
Other diseases included primary biliary cirrhosis (PBC) or autoimmune hepatitis (AIH). 
Staging features are shown, including Portal vein thrombosis (PVT), extrahepatic disease 
(EH), Barcelona Clinic for Liver Cancer (BCLC) stage and ECOG performance status (PST). 
Ablation was using microwave. Arterial treatment was drug eluting bead transarterial 
chemoembolization (DEB-TACE) or systemmic internal radiotherapy treatment (SIRT). 
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Table 2.  Predictors of Survival 
 
 
In the multivariate cox regression analysis, variables with a p value <0.05 on univariate 
analysis were included.  For categorical variables (cat) the comparator was that variable with 
the best outcome i.e. no portal vein thrombosis (PVT) or extrahepatic disease (EHD. 
Significance and Hazards Ratio (HR) with upper and lower 95% confidence intervals (CI) are 
shown.  
(A) The presence of EHD, PVT and CTC number were independently associated with 
survival, although the HR for CTC number was small. (B). When CTCs were considered as a 
categorical rather than a continuous variable, comparing CTC 0 or 1 to cases with CTC >1, 
the HR was similar to that for PVT (B). 
 
 
2A  
 
Univariat
e 
Analysis 
Multivariate Analysis  
CTC considered as a 
continuous variable 
2B  Multivariate Analysis 
CTC considered as a 
categorical variable 
  95% CI    95% CI 
    p  HR  Uppe
r 
Lower  p  HR  Uppe
r 
Lowe
r 
CTC number 
4ml  
0.043  0.02
5 
1.00
2 
1.000  1.003  (Not included) 
CTC >1 / 4ml  <0.0001  (Not included)  0.04
9 
2.33
5 
1.005  5.425 
Age (median 
year) 
0.217                 
BMI  0.474                 
T2DM  0.939                 
Cirrhosis  0.643                 
No of tumours  0.071                 
Size of largest 
(cm) 
<0.0001  0.17
4 
1.00
5 
0.998  1.013  0.06
5 
1.00
7 
1.000  1.014 
PVT (cat)  0.002  0.00
5 
3.56
8 
1.467  8.679  0.02
3 
2.57
5 
1.140  5.818 
EHD (cat)  0.001  0.00
3 
4.16
3 
1.634  10.60
5 
0.12
2 
1.99
9 
0.831  4.807 
Ascites    0.061                 
Encephalopath
y 
0.183                 
AFP (median)  0.065                 
Albumin (g/l)  0.120                 
Bilirubin 
(µmol/l) 
0.582                 
Prothrombin 
time 
0.566                 
PST (cat)  0.127                 
Treatment (cat)  0.072                 
BCLC stage  0.187                 
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Figure 1. Heterogenous expression of biomarkers in HCC cell lines
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At‐Risk Patients
CTCs ≤1/4 ml  37 33 19 7 3 2
CTCs >1/4 ml  32 17 8 4 2 1
a) CTCs ≤1/4 ml CTCs >1/4 ml 
p<0.0001
CTCs ≤1/4 ml 
CTCs >1/4 ml 
P=0.006
At‐Risk Patients
CTCs ≤1/4 ml  36 18 8 3 2 2
CTCs >1/4 ml  29 7 2 0 0 0
At‐Risk Patients
CTCs ≤1/4 ml  17 10 3 21 1 1
CTCs >1/4 ml  12 1 0 0 0 0
CTCs ≤1/4 ml 
CTCs >1/4 ml 
P=0.002
At‐Risk Patients
CTCs ≤1/4 ml  17 16 9 4 4 1
CTCs >1/4 ml  12 7 2 0 0 0
CTCs ≤1/4 ml 
p<0.0001
CTCs >1/4 ml 
b)
c) d)
Survival Time (months)
Survival Time (months)
TTP (months)
TTP (months)
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